390 related articles for article (PubMed ID: 20367273)
21. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
23. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
Oppenheimer F; Gonzalez-Molina M; Rubio M
Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
25. New prophylactic treatment strategy for cytomegalovirus disease.
Lake KD
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
[TBL] [Abstract][Full Text] [Related]
26. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
28. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
29. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
30. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
Cochrane AB
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
[TBL] [Abstract][Full Text] [Related]
31. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
32. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
Razonable RR
Infect Dis Clin North Am; 2013 Jun; 27(2):317-42. PubMed ID: 23714343
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
35. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Falagas ME; Vardakas KZ
Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
[TBL] [Abstract][Full Text] [Related]
36. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
Freeman RB; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Heaton N;
Transplantation; 2004 Dec; 78(12):1765-73. PubMed ID: 15614149
[TBL] [Abstract][Full Text] [Related]
38. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Asberg A; Humar A; Jardine AG; Rollag H; Pescovitz MD; Mouas H; Bignamini A; Töz H; Dittmer I; Montejo M; Hartmann A;
Am J Transplant; 2009 May; 9(5):1205-13. PubMed ID: 19422345
[TBL] [Abstract][Full Text] [Related]
40. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]